Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer
Yuki Tsukazaki(Tokushima University), Yasuhiko Nishioka(Tokushima University), Kayoko Hase(Tokushima Municipal Hospital), Atsushi Mitsuhashi(Tokushima University), Yuko Toyoda(Tokushima University), Yohei Yabuki(Tokushima University), Eiji Takeuchi(Higashi Nagoya National Hospital), Seiya Ichihara(National Hospital Organization Kochi National Hospital), Shoko Harada(Tokushima Municipal Hospital), Takashi Haku(Tokushima Prefectural Central Hospital), Hirokazu Ogino(Tokushima University), Ryohiko Ozaki(Tokushima University), Takeshi Imakura(Tokushima Prefectural Central Hospital), Masaki Hanibuchi(Tokushima University), Yutaka Morita(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Yoshio Okano(Toneyama National Hospital), Rikako Matsumoto(Tokushima University), Hiroto Yoneda(Tokushima University), Yugo Matsumura(National Hospital Organization Kochi National Hospital), Ei Ogawa(Tokushima University)
Cited by 8
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine -1-phosphate therapy
|Nature Medicine|2000|596
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175